| Literature DB >> 31842511 |
Sajal K Saha1,2, Chris Barton1, Shukla Promite3, Danielle Mazza1,2.
Abstract
The scope of antimicrobial stewardship (AMS) surveys on community pharmacists (CPs) is uncertain. This study examines the breadth and quality of AMS survey tools measuring the stewardship knowledge, perceptions and practices (KPP) of CPs and analyse survey outcomes. Following PRISMA-ScR checklist and Arksey and O'Malley's methodological framework seven medical databases were searched. Two reviewers independently screened the literatures, assessed quality of surveys and KPP outcomes were analysed and described. Ten surveys were identified that assessed CPs' AMS perceptions (n = 7) and practices (n = 8) but none that assessed AMS knowledge. Three survey tools had been formally validated. Most CPs perceived that AMS improved patient care (median 86.0%, IQR, 83.3-93.5%, n = 6), and reduced inappropriate antibiotic use (84.0%, IQR, 83-85%, n = 2). CPs collaborated with prescribers for infection control (54.7%, IQR 34.8-63.2%, n = 4) and for uncertain antibiotic treatment (77.0%, IQR 55.2-77.8%, n = 5). CPs educated patients (53.0%, IQR, 43.2-67.4%, n = 5) and screened guideline-compliance of antimicrobial prescriptions (47.5%, IQR, 25.2-58.3%, n = 3). Guidelines, training, interactions with prescribers, and reimbursement models were major barriers to CP-led AMS implementation. A limited number of validated survey tools are available to assess AMS perceptions and practices of CPs. AMS survey tools require further development to assess stewardship knowledge, stewardship targets, and implementation by CPs.Entities:
Keywords: AMS survey tools; antimicrobial stewardship; community pharmacist; knowledge; perceptions; practices
Year: 2019 PMID: 31842511 PMCID: PMC6963969 DOI: 10.3390/antibiotics8040263
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Figure 1Selection of study.
Characteristics and validity of survey studies.
| Study Author | Country and Population | Methods and Mode | Response Rate | Questionnaire Developed by | Validation and no. of Questions | Outcome Domain | Reliability | Quality |
|---|---|---|---|---|---|---|---|---|
| Rizvi et al., 2018 | Australia | Cross-sectional survey | 61% (85/140) | Rizvi et al. | Validated | K, Per, P, B, F | + | High |
| Khan et al., 2016 | Malaysia | Cross-sectional survey | 83.5% (188/225) | Khan et al. | Validated | Per, P | + | High |
| Erku et al., 2016 | Ethiopia | Cross-sectional survey | 86.6% (334/389) | Khan et al. | Validated | Per, P | + | High |
| Pawluk et al., 2015 | Qatar | Cross-sectional survey | 51.6% (32/62) | Pawluk et al. | Developed by literature review | Per, F | - | Low |
| Avent et al., 2018 | Australia | Cross-sectional survey | - | Avent et al. | Not validated | P, B | - | Low |
| Sarwar et al., 2018 | Pakistan | Cross-sectional survey | 96.6% (400/441) | Sarwar et al. and Khan et al. | Validated | A, P, B, F | + | High |
| Wilcock et al., 2017 | UK | Cross-sectional survey | 91.9% (57/62) | Wilcock et al. | Not validated | P, B | - | Low |
| Rehman et al., 2018 | Pakistan | Cross-sectional survey | 37% | Khan et al. | Validated | Per, P | + | Medium |
| Hancock et al., 2016 | UK | cross sectional survey | - | Hancock et al. | Not validated | A, P, B, F | - | Medium |
| Lee et al., 2017 | Canada | Cross sectional survey | 12.4% (138/1109) | Lee et al. | Not validated | K, A | - | Low |
K = knowledge, A = attitudes, Per = perception, P = practice, B = barriers, F = facilitators, Reliability (Cronbach alfa): measured (+), not measured (−).
Quality assessment of survey studies.
| N | Criteria | Reviewer (R) | Rizvi et al., 2018 | Khan et al., 2016 | Erku et al., 2016 | Pawluk et al., 2015 | Avent et al., 2018 | Sarwar et al., 2018 | Wilcock et al., 2017 | Rehman et al., 2018 | Hancock et al., 2016 | Lee et al., 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Was there a clearly defined research question? | R1 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| R2 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||
| 2 | Did the authors select samples that well represent the population to be studied? | R1 | ✓ | ✓ | ✓ | x | x | ✓ | x | x | ✓ | x |
| R2 | ✓ | ✓ | ✓ | x | ? | ✓ | x | x | ✓ | x | ||
| 3 | Did the authors use designs that balance costs with errors? | R1 | ? | x | ? | x | ? | ? | x | ? | ? | ? |
| R2 | ? | x | x | x | ? | ? | x | ? | ? | ? | ||
| 4 | Did the authors describe the research instrument? | R1 | ✓ | ✓ | ✓ | x | x | ✓ | x | ✓ | ✓ | ✓ |
| R2 | ✓ | ✓ | ✓ | ? | x | ✓ | x | ✓ | ✓ | ? | ||
| 5 | Was the instrument pretested? | R1 | ✓ | ✓ | ✓ | ✓ | x | ✓ | x | ✓ | ? | x |
| R2 | ✓ | ✓ | ✓ | ✓ | x | ✓ | ? | ✓ | ? | ? | ||
| 6 | Were quality control measures described? | R1 | ✓ | ? | ✓ | x | ? | ✓ | x | ✓ | ✓ | x |
| R2 | ✓ | ? | ✓ | x | x | ✓ | x | ? | ✓ | ? | ||
| 7 | Was the response rate sufficient to enable generalizing the results to the target population? | R1 | ✓ | ✓ | ✓ | x | ? | ✓ | x | x | x | x |
| R2 | ✓ | ✓ | ✓ | x | x | ✓ | x | x | x | x | ||
| 8 | Were the statistical, analytic, and reporting techniques appropriate to the data collected? | R1 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ? | x | ✓ | ✓ |
| R2 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | x | x | ? | ✓ | ||
| 9 | Was evidence of ethical treatment of human subjects provided? | R1 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| R2 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||
| 10 | Were the authors transparent to ensure evaluation and replication? | R1 | ✓ | ✓ | ✓ | x | x | ✓ | x | ✓ | x | x |
| R2 | ✓ | ✓ | ? | x | x | ✓ | x | ✓ | ? | x | ||
| Quality of survey studies | H | H | H | L | L | H | L | M | M | L | ||
H = high quality; M = medium quality; L = low quality; ? = unclear; x = no; ✓ = yes. Scoring: high quality (score ≥ 8), medium quality (5 ≤ score < 8) and low quality (score < 5).
Perceptions of community pharmacists (CPs) towards antimicrobial stewardship (AMS).
| Items | Median (%) | IQR |
|---|---|---|
| AMS improve patient care ( | 86.0 | 83.3–93.5 |
| AMS reduce inappropriate use ( | 84.0 | 83–85 |
| CPs have important role in AMS ( | 93.0 | 90.8–94.7 |
| Willing to participate in future AMS initiatives ( | 87.8 | 83.6–90.3 |
| AMS should be practiced at community pharmacy level ( | 78.0 | 52.5–79.3 |
| AMS reduce infection associated costs ( | 78.0 | – |
| Health-care professionals other than prescribers need to understand AMS ( | 69.0 | 66.8–84.5 |
| Individual efforts at AMS have minimal impact on the antimicrobial resistance problem ( | 51.4 | 40.7–69.4 |
AMS practices of CPs.
| AMS Practice Components | % CPs Often or Always Do This Practice | |
|---|---|---|
| Median | IQR | |
|
| ||
| Collaborate with prescribers in case of uncertainty in appropriateness of antibiotic prescription ( | 77.0 | 55.2–77.8 |
| Collaborate with other health care professionals for infection control and AMS ( | 54.7 | 34.8–63.2 |
| Contacting prescriber when patient is allergic to prescribed antibiotic ( | 98.6 | – |
| Contacting prescriber when choice of antibiotic may not be optimal ( | 46.5 | – |
|
| ||
| Provide antibiotic information to patients ( | 56 | – |
| Educate patients on the use of antimicrobials and drug resistance issues ( | 53.0 | 43.2–67.4 |
| Provide clear message on expected side effect of using antibiotics ( | 86 | – |
| Provide advice to the patients when it would be appropriate to use repeat ( | 82.9 | – |
|
| – | |
| Dispense antimicrobials without prescription ( | 34.1 | 19.4–47.0 |
| Screen antimicrobial prescription in accordance with guidelines before dispensing ( | 47.5 | 25.2–58.3 |
| Consider clinical safety parameters (drug interaction, allergy, ADRs) before dispensing ( | 68.7 | 53.6–70.7 |
| Evaluate prescription according to good dispensing practice guidelines ( | 33.4 | – |
| Refer patients to general practitioners when symptoms are suggestive of an infection ( | 99 | – |
| Recommending over the counter (OTC)/self-care treatment to patient with infections not needing antibiotics ( | 95.8 | – |
| Do not dispense delayed antibiotic prescription within 24 h of seeing doctor ( | 60 | – |
| Dispensed antibiotics for longer durations than prescribed by physicians ( | 18.4 | 13.6–23.2 |
|
| ||
| Take part in AMS campaign/awareness movement ( | 40.9 | 20.4–41.5 |
Barriers to and facilitators in implementing AMS by CPs.
| Barriers | Facilitators | Proposed Recommendation to Improve AMS in Community Pharmacy |
|---|---|---|
|
|
|
|
| Education and training | Familiarity of AMS term | Provision of AMS training as a part of the CPD program |
|
|
|
|
| Prescriber-CP interaction | Positive intention to collaborate with prescribers | GP-CP network (policy guided) |
|
|
|
|
| provision of AMS campaign | Professional organisation’s training modules and tool kits (e.g., NPS Medicine Wise, CDC, NHS) | Restriction on OTC sale of antibiotics |
|
|
|
|
| Accessibility of patient’s records and laboratory data | - | Decision support tools (antimicrobials review tools) |
|
|
|
|
| Reimbursement models | Remuneration for pharmacies involved in AMS programs |